Genetic products differentially expressed in tumors and use thereof
The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which the genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.
1. A method of treating a cancer in a patient, comprising:
administering to the patient an antibody binding to a protein, wherein the antibody is coupled to a therapeutic agent, the protein having an amino acid sequence selected from the group consisting of:
(a) an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 19-21 and 54-57;
(b) an amino acid sequence selected from the group consisting of SEQ ID NOs: 22-24 and 58-61; and
(c) an amino acid sequence encoded by a nucleic acid which is degenerate with respect to the nucleic acid of (a);
wherein the cancer is characterized by expression or abnormal expression of a protein comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 22-24 and 58-61.
2. The method as claimed in claim 1 wherein the therapeutic agent is a toxin.
3. The method as claimed in claim 1 , wherein the antibody is a monoclonal antibody.
4. The method as claimed in claim 1 , wherein the antibody is a chimeric or humanized antibody.
5. The method as claimed in claim 1 , wherein the antibody is an antigen binding fragment of an antibody.
6. The method as claimed in claim 1 , wherein the cancer is selected from the group consisting of seminoma, melanoma, teratoma, glioma, colorectal cancer, breast cancer, prostate cancer, cancer of the uterus, ovarian cancer, lung cancer, a kidney cell carcinoma, a cervical carcinoma, a colon carcinoma, a mammary carcinoma, a prostate carcinoma, a bronchial carcinoma, an ovarian carcinoma, and a thyroid carcinoma.
7. A method of treating a metastasizing tumor in a patient comprising:
administering to the patient an antibody that binds to TPTE, wherein the antibody is coupled to a therapeutic agent, the TPTE having an amino acid sequence selected from the group consisting of:
(a) an amino acid sequence encoded by the nucleic acid sequence set forth in SEQ ID NO: 19;
(b) an amino acid sequence selected from the group consisting of SEQ ID NOs: 22-24 and 58-61; and
(c) an amino acid sequence encoded by a nucleic acid which is degenerate with respect to the nucleic acid of (a);
wherein the tumor is characterized by expression or abnormal expression of a tumor-associated antigen comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 22-24 and 58-61.
8. The method as claimed in claim 7 wherein the therapeutic agent is a toxin.
9. The method as claimed in claim 7 , wherein the antibody is a monoclonal antibody.
10. The method as claimed in claim 7 , wherein the antibody is a chimeric or humanized antibody.
11. The method as claimed in claim 7 , wherein the antibody is an antigen binding fragment of an antibody.
12. A method of treating a cancer in a patient, comprising:
administering to the patient a pharmaceutical composition including an antibody that is coupled to a therapeutic agent and that is capable of selectively binding to cells expressing a protein, the protein having an amino acid sequence selected from the group consisting of:
(a) an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 19-21 and 54-57;
(b) an amino acid sequence selected from the group consisting of SEQ ID NOs: 22-24 and 58-61; and
(c) an amino acid sequence encoded by a nucleic acid which is degenerate with respect to the nucleic acid of (a);
wherein the cancer is characterized by expression or abnormal expression of a protein comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 22-24 and 58-61.
13. The method as claimed in claim 12 , wherein the therapeutic agent is a toxin.
14. The method as claimed in claim 12 , wherein the antibody is a monoclonal antibody.
15. The method as claimed in claim 12 , wherein the antibody is a chimeric or humanized antibody.
16. The method as claimed in claim 12 , wherein the antibody is an antigen binding fragment of an antibody.
17. The method of claim 1 , wherein the antibody binds the protein within an extracellular domain of the protein.
18. The method of claim 17 , wherein the antibody binds to an epitope within the amino acid sequence according to SEQ ID NO: 81 or 82.
19. The method as claimed in claim 1 , wherein the cancer is selected from the group consisting of a melanoma, a mammary carcinoma, a prostate carcinoma, a bronchial carcinoma, an ovarian carcinoma, or a cervical carcinoma.
20. The method of claim 7 , wherein the antibody binds to TPTE within an extracellular domain of the protein.
21. The method of claim 20 , wherein the antibody binds to an epitope within the amino acid sequence according to SEQ ID NO: 81 or 82.
22. The method as claimed in claim 7 , wherein the cancer is selected from the group consisting of a melanoma, a mammary carcinoma, a prostate carcinoma, a bronchial carcinoma, an ovarian carcinoma, or a cervical carcinoma.
23. The method of claim 12 , wherein the antibody binds the protein within an extracellular domain of the protein.
24. The method of claim 23 , wherein the antibody binds to an epitope within the amino acid sequence according to SEQ ID NO: 81 or 82.
25. The method as claimed in claim 12 , wherein the cancer is selected from the group consisting of a melanoma, a mammary carcinoma, a prostate carcinoma, a bronchial carcinoma, an ovarian carcinoma, or a cervical carcinoma.